Eoneren ANI Pharmaceuticals ( NASDAQ: ANIP ) announced Tuesday it has completed the purchase of royalty obligations linked to Iluvien and Yutiq, two eye disease therapies the company added with its $5.50 per share acquisition of Alimera Sciences in 2024. Accordingly, ANI Pharmaceuticals (.